8,357 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by CenterBook Partners LP

CenterBook Partners LP purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 8,357 shares of the company’s stock, valued at approximately $613,000.

Several other hedge funds also recently modified their holdings of the company. State of New Jersey Common Pension Fund D acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $2,258,000. PNC Financial Services Group Inc. raised its position in Mirum Pharmaceuticals by 183.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,262 shares of the company’s stock valued at $93,000 after purchasing an additional 817 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in Mirum Pharmaceuticals in the third quarter worth $22,041,000. Caprock Group LLC bought a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $353,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at $503,000.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $105.16 on Friday. The stock has a market cap of $5.40 billion, a P/E ratio of -122.28 and a beta of 0.49. The stock’s 50-day moving average price is $90.24 and its two-hundred day moving average price is $77.77. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $107.41.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, Stifel Nicolaus boosted their price objective on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.17.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $99,994.40. Following the sale, the senior vice president owned 4,503 shares of the company’s stock, valued at $465,159.90. This trade represents a 17.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Peetz sold 9,108 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,136 shares of company stock valued at $4,352,029 over the last three months. Insiders own 14.36% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.